Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (55)	7/25/1998 11:29:00 PM
From: Bluegreen	Read Replies (1) \| Respond to of 1475

This comes on the heals of the guy that got a larynx transplant. There will definitely be an EXPANDING need for immune system modulators.>>>>>>>>>>>>>>> LOUISVILLE, Ky. (AP) - After three years of work and two years of animal experiments, researchers have been given permission to attempt the world's first successful hand transplant. While surgeons have been able to reattach severed limbs following accidents for years, they have never been able to successfully transfer a limb from a donor to a living recipient. But a research team in Louisville is hoping they can accomplish the feat within the next three to six months. ''Potentially, this procedure could be a breakthrough on par with the first kidney and heart transplants,'' said Gordon Tobin, a University of Louisville professor of surgery. ''It all depends on how successful it proves to be once it is done and perfected.'' The University of Louisville School of Medicine Human Studies Committee and Jewish Hospital Institutional Review Board granted approval after researching the idea for more than three years and analyzing the findings of an international symposium on the idea held last November. An ideal candidate for the surgery would be someone between 18 and 65 who has had part of an arm amputated below the elbow. A donor hand would be sought through existing organizations that coordinate transplants of organs such as hearts, lungs and kidneys. Researchers said the eight- to 12-hour procedure should not be as tricky as a typical limb reattachment, or replantation, which often involves crushed or mangled bones, tendons and ligaments. But at least one surgeon expressed concern over the plan. ''It's very, very risky and I think they're pressing the envelope with this,'' said Matthew Tomaino, chief of microsurgery for the University of Pittsburgh's orthopedic surgery department. Tomaino cited the risk of death from drugs given to prevent the body from rejecting the limb. The drugs suppress the immune system. ''The risks from taking these drugs, which the recipients will have to take for the rest of their lives, have not warranted the transplant of a non-vital organ,'' he said Thursday. Tomaino also said the chances of the recipient ever experiencing much, if any, real feeling in the transplanted hand are minimal. Members of the team, however, believe that a recipient potentially could experience some motion six to eight weeks after surgery, a wider range of motion after six months and some sensation after a year. South American doctors attempted a similar procedure in 1964 but the donor hand was rejected in only 14 days. Medical and technological advancements have made the procedure more feasible and the risk of rejection more manageable, the doctors said. Tobin said the transplant could lead to other breakthroughs. ''The potential applications, as one gets into other body parts, are limitless,'' Tobin said. ''If it can be done with a hand, it can be done with any part of the human anatomy.''<<<<<<<<<<<<<In other words once again EXPANDING use for Biotransplant's products if approved. Anybody aware of any animal studies also on Biotransplant's products and protective effect for transplanted Beta cells or the whole pancreas? AP-NY-07-24-98 0131EDT

To: scaram(o)uche who wrote (55)	7/26/1998 12:49:00 AM
From: Larry Liebman	Respond to of 1475

Richard. I've been eyeballing PCOP the last few weeks as it descended to $13+. I called the company and they stated that Tang at Alex Brown had lowered its' price target while maintaining a "strong buy". The reason given was that MSI had a significant revenue flow via Asia which he believed could reduce MSI revenues by about 25% this quarter. I just received an investor packet from PCOP and was rather surprised at the scope of MSI. As with ARQL, the impression I had was that they could leverage their technology beyond the pharmaceutical arena. I was wondering if you saw PCOP as one of your elite/cutting edge companies. I was also wondering if you had any inclination/reservation/enthusiasm for LGND or ISIP. Your thoughts, as always, would be appreciated.

To: scaram(o)uche who wrote (55)	8/1/1998 6:20:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1475

MEDI first quarter letter to shareholders...... medimmune.com And cut and paste from the MEDI annual report....... Despite significant improvements in the transplantation arena, life-threatening complications such as GvHD and rejection remain serious medical problems. GvHD is the most common complication of bone marrow or stem cell transplantation when immune cells of the foreign graft, i.e., the donor bone marrow, trigger an immune reaction against the tissues of the recipient. The number of allogeneic bone marrow and stem cell transplants has increased significantly over the last few years to over 10,000 annually and GvHD occurs in approximately 50 percent of them. BTI-322 has demonstrated potential clinical benefit in several Phase 1 / 2 clinical trials conducted in the U.S. and Europe. In particular, results of the most recent trial evaluating BTI-322 for treatment of GvHD demonstrated that 55 percent of patients showed improvement in the grade of GvHD. These studies with BTI-322 prompted the Company's plans to conduct a Phase 2 study with MEDI-507 to evaluate extended dosing in patients with GvHD. MedImmune and collaborator, BioTransplant, Incorporated, believe that MEDI-507's ability to modulate T cell responses could make it an ideal candidate for treating certain autoimmune diseases. Autoimmune diseases include conditions such as psoriasis, rheumatoid arthritis, multiple sclerosis and Type 1 diabetes. A Phase 1 clinical study to evaluate MEDI-507 in patients with psoriasis recently began and, based on the results of that s t u d y, the Company will consider pursuing other autoim-mune indications with MEDI-507. MEDIMMUNE IS EVALUATING SEVERAL CLINICAL OPPORTUNITIES FOR MEDI-507, INCLUDING ITS POTENTIAL USE IN PREVENTING ORGAN TRANSPLANT REJECTION, TREATMENT OF GRAFT-VERSUS-HOST DISEASE (GVHD) AND TREATMENT OF CERTAIN AUTOIMMUNE DISORDERS.